Gilead Sciences (NQ:GILD)

Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma

Via 3BL Media

December 13, 2021

Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma

December 11, 2021

Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma

December 11, 2021

Gilead Sciences Commits to Electrifying Its Fleet

November 16, 2021

Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma

Via 3BL Media

December 11, 2021

Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study

December 10, 2021

HIV Advisory Council in Australia Taps Diverse Community Perspectives

December 09, 2021

FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 8, 2021 – USA News Group – Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit...

Via 3BL Media

Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks

December 08, 2021

Via FinancialNewsMedia

Gilead Sciences Ranked No. 6 overall, and No. 2 in Health Care & Life Sciences Industry, in Newsweek's List of Most Responsible American Companies

December 07, 2021

Gildead Sciences Is Proud to Be a Presenting Partner of National AIDS Memorial's World AIDS Day: December 1, 2021

Via 3BL Media

December 01, 2021

Via 3BL Media

Gilead Sciences Added to the Dow Jones Sustainability World Index

November 30, 2021

Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS

Via 3BL Media

Topics Stocks

November 29, 2021

Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line

November 23, 2021

The Importance of Self Advocacy in Breast Cancer: Janelle's Story

November 23, 2021

Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta

Via 3BL Media

Topics Product Recall

November 19, 2021

Gilead Sciences to Present at Upcoming Investor Conference

November 18, 2021

Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration

November 18, 2021

India's Efforts to Help End Hepatitis C Starts With Prison Population

November 18, 2021

Via 3BL Media

Topics Death

Kerri Fitzpatrick Puts Patients Front and Center

November 12, 2021

BA Insight for Amazon OpenSearch Service and BA Insight for Amazon Kendra Available Immediately in AWS Marketplace

Via 3BL Media

November 12, 2021

BOSTON - Nov. 12, 2021 - PRLog -- BA Insight has today announced availability of two Amazon Web Services Marketplace offerings: BA Insight for Amazon OpenSearch Service and BA Insight for Amazon...

Via PRLog

Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint

November 10, 2021

Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting®

November 09, 2021

Thumbi Ndung'u on Thinking Beyond Lifelong Treatment in HIV

November 09, 2021

Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline

Via 3BL Media

November 04, 2021

Healthcare Nanotechnology (Nanomedicine) Market Next Big Thing : Gilead Sciences, Pfizer, 3M ↗

November 10, 2021

The latest independent research document on Worldwide Healthcare Nanotechnology (Nanomedicine) examine investment in Market.

Via SBWire

'Inside the Innovation:' Oncology Leaders Discuss Life at Gilead

November 02, 2021

Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting

Via 3BL Media

October 29, 2021

Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer

October 28, 2021

Gilead Sciences Announces Third Quarter 2021 Financial Results

October 28, 2021